149 related articles for article (PubMed ID: 10744453)
1. The role of urine cytology in the assessment of patients with lower urinary tract symptoms.
Cannon A; Hammonds JC
BJU Int; 2000 Feb; 85(3):380. PubMed ID: 10744453
[No Abstract] [Full Text] [Related]
2. [Urinary cytology in tumors of the urinary tract].
Hüsermann M; Sommer E; Blumberg A
Schweiz Med Wochenschr; 1979 Mar; 109(9):304-8. PubMed ID: 571143
[TBL] [Abstract][Full Text] [Related]
3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
4. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
5. Urinary cytology: device capabilities and requirements.
Koss LG; Bartels PH
Anal Quant Cytol; 1980; 2(1):59-65. PubMed ID: 6990848
[TBL] [Abstract][Full Text] [Related]
6. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
7. [Clarification of pathologic urine findings. urine inspection in the third millennium].
Füessl HS
MMW Fortschr Med; 2003 May; 145(21):4-8. PubMed ID: 12845857
[No Abstract] [Full Text] [Related]
8. The role of urine cytology in the assessment of lower urinary tract symptoms.
Kouriefs C; Leris AC; Mokbel K; Carpenter R
BJU Int; 2000 Jun; 85(9):1155. PubMed ID: 10939871
[No Abstract] [Full Text] [Related]
9. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
10. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
11. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
12. Bladder cancer detection using FISH (UroVysion assay).
Halling KC; Kipp BR
Adv Anat Pathol; 2008 Sep; 15(5):279-86. PubMed ID: 18724101
[TBL] [Abstract][Full Text] [Related]
13. A side by side comparison of cytology and biomarkers for bladder cancer detection.
Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V
J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic adenoma identified on urine cytology using PAX-2 immunostaining.
Herlitz LC; Tong GX; Hamele-Bena D; Greenebaum E
Diagn Cytopathol; 2008 Jan; 36(1):47-9. PubMed ID: 18064687
[TBL] [Abstract][Full Text] [Related]
15. The role of urinary cytology for detection of bladder cancer.
Planz B; Jochims E; Deix T; Caspers HP; Jakse G; Boecking A
Eur J Surg Oncol; 2005 Apr; 31(3):304-8. PubMed ID: 15780568
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hematuria.
Koss LG
JAMA; 1982 Mar; 247(9):1274. PubMed ID: 7062537
[No Abstract] [Full Text] [Related]
17. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
18. [Urinary tumor marker for urothelial cancer].
Ohtani M; Iwasaki A; Shiraiwa H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
[TBL] [Abstract][Full Text] [Related]
19. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
20. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]